Regulus Therapeutics (RGLS) : Traders are negative on Regulus Therapeutics (RGLS), as it has 12.5% of short positions outstanding compared to its float. The total shorts have reduced by -80,215 shares, which is a -1.9% reduction. From Jul 29, 2016, to August 15, 2016, the shorts came down from,4,343,527 to 4,263,312 shares. While the daily trading volume of the stock is 431,826, there are 10 days remaining to cover the open short positions. The short interest indicates that the traders dont see a large downside in the stock from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Regulus Therapeutics (NASDAQ:RGLS): The stock opened at $3.45 on Wednesday but the bulls could not build on the opening and the stock topped out at $3.57 for the day. The stock traded down to $3.22 during the day, due to lack of any buying support eventually closed down at $3.22 with a loss of -6.40% for the day. The stock had closed at $3.44 on the previous day. The total traded volume was 434,190 shares.
In a related news, Hagan Joseph P, COO of Regulus Therapeutics Inc., executed a transaction worth $71,900 on March 3, 2016. A total of 10,000 shares were purchased at an average price of $7.19. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Companys Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Its development programs include microRNA target miR-122, miR-21, RG-012, miR-103/107, miR-19, miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs, RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.